Gandham R, Dayanand C. D, Sheela S. R, Kiranmayee P. Impact of Oxidative Stress on Maternal Serum Apelin 13 and Endothelial Nitric Oxide Synthase in Preeclampsia. Biomed Pharmacol J 2020;13(4).

---

Manuscript received on :2-Jul-2020
Manuscript accepted on :3-Dec-2020
Published online on: 28-12-2020

---

Plagiarism Check: Yes
Reviewed by: John George Hardy  
Second Review by: Tamer Addissouky  
Final Approval by: Fai Poon  

---

How to Citeclose    |   Publication History close

 Views: (Visited 477 times, 1 visits today)    PDF Downloads: 378

Rajeev Gandham¹, C.D. Dayanand¹, S.R. Sheela² and Kiranmayee P³

¹Department of Biochemistry, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research (SDUAHER), Tamaka, Kolar, Karnataka, India-563 103.

²Department of Obstetrics and Gynecology, Sri Devaraj Urs Medical College, Sri Devaraj Urs Academy of Higher Education and Research (SDUAHER), Tamaka, Kolar, Karnataka, India-563 103.

³Department of Cell Biology and Molecular Genetics, Sri Devaraj Urs Academy of Higher Education and Research (SDUAHER), Tamaka, Kolar, Karnataka, India-563 103.

Corresponding Author E-mail: cd8905@yahoo.co.in

DOI : https://dx.doi.org/10.13005/bpj/2083

Abstract

Preeclampsia (PE) is the most common hypertensive disease of pregnancy, leads to maternal, perinatal morbidity and mortality, which accounts for 2-8% of pregnancies. Preeclampsia is characterized by new onset of hypertension and proteinuria after 20 weeks of gestation.The exact cause of preeclampsia is not clear. Aim of this study is to investigate the association between maternal serum apelin13, endothelial nitric oxide synthase, markers of oxidative stress in healthy pregnant women and preeclamptic women. This prospective study comprises 140 pregnant women consists of 70 preeclamptic women treated as cases and 70 nor motensive healthy pregnant women as controls. Five mL blood sample was collected, centrifuged to obtain serum/plasma and was stored at -80°C for further testing. Plasma was used for Ferric reducing antioxidant power (FRAP) assay and complete blood countwas done. Routine parameters like random blood sugar, renal profile, liver enzymes, lactate dehydrogenase (LDH), malondialdehyde (MDA), nitric oxide (NO), apelin 13 and endothelial nitric oxide synthase (eNOS)were also analyzed. Corresponding urine sample was tested for protein. Study results showed lower gestational age (36.99±3.48 weeks) and demographic details such as elevated blood pressure [systolic (156.80±13.71 mmHg),diastolic (101.97±10.70 mmHg),and mean arterial pressure (120.88±11.02 mmHg)], BMI (27.42±3.80 kg/m²) and pulse rate (87.68±5.74 bpm) were observed in cases than controls. The biological markers namely serum MDA (18.57±7.52μmoles/L) levels were significantly increased and nitric oxide (6.47±1.22μmoles/L), FRAP (1292.10±525.38 mmol/L), apelin 13(312.42±189.00pg/ml) andeNOS(5.07±2.30 ng/ml)levels were significantly decreased in cases.Mean arterial pressure was negatively correlatedwithApelin 13 (r=-0.179), NO (r=-0.065), FRAP (r=-0.169), and birth weight (r=-0.281) and eNOS (r= 0.013), MDA (r= 0.022) were positively correlated with mean arterial pressure. The study concludes that reduced levels of apelin 13, eNOS, FRAP,NO and high oxidative stress, contribute to pathogenesis of preeclampsia and adverse perinatal outcome. It also demands sufficient evidence for the functional role of apelin 13 as a target in hypertension regulation.

Keywords

Angiogenesis; Hypertension; Malondialdehyde; Nitric Oxide

Introduction

Preeclampsia (PE) is apregnancy specific complication and it causes maternal, perinatal morbidity and mortality, which accounts for 2-8% of pregnancies ^1,2. The incidence of preeclampsia in India varies from 5% to 10%³.

This disease is characterized by new onset of hypertension and proteinuria after 20 weeks of gestational period¹. The exact cause of preeclampsia is not clear. However, it includes abnormal placentation, vascular endothelial dysfunction, oxidative stress, inflammation and impaired angiogenesis ^4,5. Oxidative stress contributes further in the pathophysiology of preeclampsia. Increased oxidative stress has influence on endothelial dysfunction, systemic vascular resistance, leading to decreased placental perfusion and aggravates placental ischemia-reperfusion injury ^6-8.

Apelin protein encoded by APLN gene located on chromosome Xq25-26.1⁹. The apelinergic system role in cardiovascular homeostasisis studied ¹⁰.However, apelinrole in preeclampsia is poorly understood. The apelin and APJ/AR expression are widespread in human tissues.High levels were seen in placenta, suggesting its potential production from placenta^11-13.Biosynthesis includes apelin precursor processing into many biologically active short peptides. They are apelin precursor (77 amino acid residues), proapelin (55 amino acids) further into short apelins (apelin-36, apelin-17, apelin- 13, and apelin 12), and are potentially biological activator for APJ ^14-15. These peptides have distinct activities and shorter apelinpeptides are more potent activators for APJ ¹⁶.The activated apelinpeptides promote vasodilatation through L-arginine/eNOS/NO path way¹⁷. More over, it induces cardiac contractility, angiogenesis and suppresses aortic inflammation¹⁸. Itis believed that altered expression of apelin impairs angiogenesis process and linked to preeclampsia complications¹⁹.

Endothelial nitric oxide synthase (eNOS) catalyzes the conversion of L-arginine into nitric oxide (NO) molecule, which is a potent vasodilator,regulates blood pressure, anti-atherogenic, prevents cell adhesion and platelet aggregation^20-22. In the placenta, the high expression of NOS is seen in syncytiotrophoblast, villous endothelium, macrophages and eNOS being the predominant isoform^23-25. A few studies have reported conflicting results about either decreased eNOS levels or unchanged ^{26, 27} and differences in eNOS staining between preeclampsia and normal pregnancy.A recent studyreport also given clue about abnormalities in eNOS/NO pathway, but the role ofeNOSin preeclampsia needs to be established²⁸. Hence, measurement of oxidative stress helps to understand the balance between oxidants and antioxidants and also investigation with the maternal serum apelin13, endothelial nitric oxide synthase (eNOS) association in healthy pregnant and preeclamptic women.

Materials and Methods

Prospective case-control study design approved by Institutional Ethics Committee conducted in Department of Biochemistry in collaboration with Department of Obstetrics and Gynecology of RL Jalappa Hospital, attached to Sri Devaraj Urs Medical College, Karnataka, India. Study participants were enrolled after obtaining written informed consent. The study comprised of 140primigravida pregnant, among them 70 were normotensive pregnant women as controls and 70 preeclampticwomen were considered as cases. Demographic details and clinical history were collected for all subjects.

Pregnant with history of renal disease, liver disease, thyroid disorder, chronic systemic hypertension, gestational diabetes, hypertensive encephalopathy, cardiovascular diseases, pregnancy with fetal anomaly, multiple pregnancies, patients with smoking history and malignancy conditions were excluded. Subjects were followed until delivery. Any adverse perinatal outcomes including respiratory distress syndrome (RDS), intrauterine death (IUD), and birth weight were recorded.

Preeclampsia Diagnosis

Preeclampsia was diagnosed according to the ACOG guidelines (ACOG practice bulletin 2013),with blood pressure of systolic ≥140 and diastolic ≥90 mmHg noted for the first time during pregnancy on 2 occasions at least 4 hours apart, after 20 weeks of gestation with proteinuria of ≥300 mg/24 hours or 1+ proteinby dipstick method or in the absence of proteinuria, the following findings were considered; thrombocytopenia (a platelet count <100,000/μL), renal insufficiency, hepatic dysfunction, symptoms associated with cerebral or ophthalmic and edema ²⁹.

Under aseptic conditions, 5 ml venous blood was collected, aliquoted into plain tube (3 mL) and EDTA (2mL) tubes from the subjects visiting to Department of Obstetrics and Gynecology for antenatal check-up. Blood samples were allowed to stand for 30 minutes, centrifuged at 3000 rpm for 10 minutes to obtain the clear serum. Thus, obtained clear serum was stored at -80°C for further testing. Complete blood count was done by using EDTA blood. Plasma was used for the FRAP assay. Serum was used for the estimation of RBS (GOD-POD),urea (urease), creatinine (sarcosine oxidase), uric acid (uricase), AST (IFCC), ALT (IFCC), LDH (kinetic), malondialdehyde (MDA) (Thiobarbituric acid reactive substances), nitric oxide (Griess reaction), and apelin 13, eNOS by ELISA. Five mL of corresponding urine sample was collected for urinary protein analysis by dipstick method. Body mass index (BMI) was calculated and fetal outcome was recorded.

Determination of maternal serum apelin-13

The serum concentration of apelin13 (SiNCERE Catalogue No：E13652182, China) in each sample was detected by using sandwich ELISA kitas per the manufacturer’s instructions.

Determination of maternal serum eNOS

The serum concentration of eNOS(SiNCERECatalogue No：E13650645, China) in each sample was detected by using sandwich ELISA kit as per the manufacturer’s instructions.

Statistical Analysis

The data was represented as Mean ± SD. Mann-Whitney U test was used for non-normally distributed variables. Spearman’s correlation was used to find the association of variables. Interquartile ranges were used for skewed parameters. P value <0.05 considered as significant. Data was analyzed by using SPSS software, version 22.0.

Results

No significant change in maternal age. Gestational age (36.99±3.48 weeks) was low in preeclampsia compared with healthy pregnant. Systolic (156.80±13.71 mmHg) and diastolic (101.97±10.70 mmHg), mean arterial pressure (120.88±11.02 mmHg), BMI (27.42±3.80 kg/m²) and pulse rate (87.68±5.74 bpm) were significantly increased in preeclampsia compared with controls(Table 1).

Table 1: Comparison of baseline characteristics between preeclampsia and healthy pregnant women.

*Significant

BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, MAP: Mean Arterial Pressure, WBC: White Blood Cell, RBS: Random Blood Sugar, AST: Aspartate Transaminase, ALT: Alanine Transaminase, LDH: Lactate Dehydrogenase

Mean levels of serum MDA (18.57±7.52μmoles/L), uric acid (5.97±1.84 mg/dL), ALT (12.75 [17-22 IU/L]), and LDH (313.01±161.50 IU/L) were increased significantly in preeclampsia compared to control group. Mean levels of serum NO (6.47±1.22μmoles/L) and FRAP (1292.10±525.38 mmol/L) were decreased significantly in preeclamptic women compared with control group. Mean level of maternal serum apelin13 (312.42±189.00pg/mL) and eNOS (5.07±2.30 ng/mL) were decreased significantly in preeclamptic women compared with control group (Table2).

Table 2: Comparison of biochemical parameters between preeclampsia and healthy pregnant women.

* Significant

MDA: Malondialdehyde,FRAP: Ferric Reducing Ability of Plasma, NO: Nitric Oxide, eNOS: endothelial Nitric Oxide Synthase.

MDA (r= 0.022), eNOS (r= 0.013), UA (r= 0.295), AST (r= 0.173), ALT (r= 0.109) andLDH (r= 0.211) were positively correlated with mean arterial pressure and FRAP (r=- 0.169), NO (r=-0.065), apelin 13 (r=-0.179) and birth weight (r=-0.281) were negatively correlated with mean arterial pressure. Among the correlations, serum uric acid and birth weight was significant (Table 3).

Table 3: Correlation of mean arterial pressure with study parameters.

* Correlation is significant at the 0.01 level (2-tailed)

Birth weight (2.50±0.64 kg) of the babies born to preeclamptic mother was decreased significantly compared with control group. Among the babies born to preeclamptic mothers, RDS and IUD were observed in 13 (18.57%) and 5 (7.14%) respectively. In normotensive mothers, RDS in 8 (11.42%) babies and IUD nil (Table 4).

Table 4: Comparison of birth weight and fetal complications of babies born to mothers with preeclampsia and healthy pregnant women.

a: Mean±SD (p<0.002), * Significant,

RDS: Respiratory distress syndrome, IUD: Intrauterine death

Discussion

Preeclampsia is a life-threatening pregnancy-specific disorder with no current treatment. In the pathophysiology of preeclampsia, role of placenta is crucial and is considered as a source of inflammation and release of vaso constrictor molecules to initiate endothelial cell injury, endothelial dysfunction and vaso constriction¹⁴.

In preeclampsia, altered spiral artery remodeling and improper invasion of trophoblasts, an inadequate blood perfusion, lead to ischemia and reperfusion injury, which increase ROS generation³⁰. Serum MDA levels represents oxidative stress, and was significantly elevated in preeclampsia compared with healthy pregnant women and correlated positively with mean arterial pressure. Total antioxidant status was decreased significantly in preeclampsia compared with healthy pregnant women and negatively correlated with mean arterial pressure. This indicates that increased lipid peroxidation is associated with decreased antioxidant protective/compensatory adaptation in preeclampsia ^31,32.

In this study, we documented the decreased maternal serum apelin 13 levels in preeclamptic women compared with control group and correlated negatively with mean arterial pressure. This indicates apelin 13 is moderately successful marker to differentiate patients with preeclampsia from healthy pregnant women. Apelin is a vasodilator and exhibits positive inotropic activity in cardiovascular system through increasing release of nitric oxide from endothelium and by antagonizing the activity of angiotensin II ¹⁵. Studies reported reduced apelin levels in other hypertensive disorders and also cardiac diseases ^33,34. Inzukuaet al., reported that apelin mRNA levels were reduced significantly in preeclamptic placentas and immuno histochemical signals for apelin and APJ receptor were also decreased ¹⁹.Cobellis L et al., reported that in normal pregnancy, placental apelin is more abundant during early gestation, suggesting its role in the regulation of fetal development and placentation ¹². Reduced levels of apelin may therefore have deleterious effects on development of the fetus⁵. Apelin is involved in the direct activation of L-arginine/ eNOS/ NO pathway [17]. Wang C et al., found that apelin treatment improved the expression of eNOS in placenta and serum levels of nitric oxide and eNOS, which were all decreased in preeclamptic rats, suggesting that restoration of eNOS/NO pathway may be involved in the ameliorative effects of apelin on preeclampsia³⁵.Aberrant angiogenesis and increased blood pressure are the hall marks of preeclampsia. Thus, one might expect decreased levels of apelin, which is angiogenic and hypotensive in preeclampsia.This observation was supported by our study results and demonstrates decreased apelin levels in preeclampsia compared with healthy pregnant women.

In this study, eNOS levels were reduced significantly in preeclampsia compared with healthy pregnant women and positively correlated with mean arterial pressure.It has been reported that eNOS in the mother and in the fetus contribute utero-placental vascular changes and elevated uterine arterial blood flow,whereas preeclampsia is associated with abnormal placentation and abnormalities in the eNOS/NO pathway²⁰.Kim YJ et al., reported that placental expression of eNOS is significantly low in preeclamptic syncytiotrophoblasts compared to normal syncytiotrophoblasts³⁶. Zawiejska A et al., reported that significantly reduced serum eNOSlevels in women with severe preeclampsia³⁷. Carolina et al., reported that exvivo-derived syncytiotrobhoblast extracellular microvesicles (STBMV) and syncytiotrobhoblast extracellular exosomes (STBEX) isolated from placental perfused lobes to have lowactivity of eNOS in preeclampsia compared with controls. Similarly, invivo-derived plasma STBMV analyzed by flow cytometry showed less STBMV bound eNOS expression in preeclampsia compared with normal pregnancy. This may contribute to the low nitric oxide levels in preeclampsia³⁸.In support of this, Choi JW et al., reported that nitric oxide levels in preeclampsia were significantly lower than the normal pregnant women. During normal pregnancy, the production of nitric oxide increases with advancing gestation and decreases in preeclampsia ³⁹.

Low birth weight wasseen in babies born to preeclamptic mothers compared to healthy pregnant women and negatively correlated with mean arterial pressure. Nadkarniet al., reported, incidence of low birth weight to be 52% among mothers with pregnancy-induced hypertension ⁴⁰. Odegardet al., reported that, preeclampsia and severe preeclampsia were linked with a 5% and 12% reduction in birth weight, respectively ⁴¹. We observed 18.57% of babies with RDS and IUD to be 7.14% which is supported by Nadkarniet al., reported 10% incidence of RDS among babies born to preeclampsia mothers ⁴⁰.

Limitations of the study

The study has limitation with respect to small size; preeclampsia subjects were not stratified based on severity of the disease, apelin and eNOS levels were measured only after the diagnosis of preeclampsia but not in early onset of preeclampsia.

Conclusion

The study results conclude that reduced levels of apelin 13, eNOS, NO and elevated oxidative stress highly contribute to the process of pathophysiology of preeclampsiaand results in adverse perinatal outcome.

Acknowledgement

We would like to thank the authorities of Sri Devaraj Urs Academy of Higher Education and Research, Kolar, Karnataka, India for supporting this doctoral study.

Conflict of Interest

There are no conflicts of interest.

Funding Sourse

There are no funding sourse

References

1. ACOG practice bulletin.Clinical Management Guidelines for Obstetrician–Gynecologists. Number 202. Obstetrics & Gynecology.,133 (1): e1-e25 (2019).
2. Nobis PN, Hajong A. Eclampsia in India through the decades. Obstet. Gynaecol. India.,66:172‑176 (2016).
   CrossRef
3. Petla LT, Chikkala R, Ratnakar K S, Kodati V, Sritharan V. Biomarkers for the management of pre-eclampsia in pregnant women. J. Med. Res.,138:60-67 (2013).
4. Daskalakis G, Papapanagiotou A. Serum Markers for the Prediction of Preeclampsia. Neurol. Neurophysiol.,6(1): 1-9 (2015).
5. Katherine D. Bortoff, ChunfangQiu, Scott Runyon, Michelle A. Williams, RanganMaitra. Decreased maternal plasma apelin concentrations in preeclampsia. pregnancy.,31(4):398-404 (2012).
   CrossRef
6. Oztas E, Ozler S, Tokmak A, Erel O, Ergin M, Uygur D, Danisman N. Oxidative stress markers in severe preeclampsia and preeclampsia-related perinatal morbidity – preliminary report. Pol.,87(6): 436-441 (2016).
   CrossRef
7. Brennan LJ, Morton JS, Davidge ST. Vascular dysfunction in preeclampsia. ,21: 4-14 (2014).
   CrossRef
8. Mert I, Oruc AS, Yuksel S, Cakar ES, Buyukkagnici U, Karaer A, Danisman N. Role of oxidative stress in preeclampsia and intrauterine growth restriction. Obstet. Gynecol. Res.,38: 658-664 (2012).
   CrossRef
9. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biophys. Res.Commun.,251:471-476 (1998).
   CrossRef
10. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in human: potential role in patients with chronic heart failure. ,121:1818-1827 (2010).
    CrossRef
11. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, Lawrie KW, Hervieu G, Riley G, Bolaky JE, Herrity NC, Murdock P, Derker JG. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. Neurochem.,84:1162-1172 (2003).
    CrossRef
12. Cobellis L, De Falco M, Mastrogiacomo A, Giraldi D, Dattilo D, Scaffa C, Colacurci N, De Luca A. Modulation of apelin and APJ receptor in normal preeclampsia-complicated placentas. Histopathol.,22:1-8 (2007).
13. Furuya M, Okuda M, Usui H, Takenouchi T, Kami D, Nozawa A, Shozu M, Umezawa A, Takahashi T, Aoki I. Expression of angiotensin II receptor-like 1 in the placentas of pregnancy-induced hypertension. J. Gynecol. Pathol.,31:227-235 (2012).
    CrossRef
14. Yamaleyeva LM, Chappell MC, Brosnihan KB, Anton L, Caudell DL, Shi S, McGee C, Pirro N, Gallagher PE, Taylor RN, Merrill DC, Mertz HL. Down-regulation of apelin in the human placental chorionic villi from preeclamptic pregnancies. J. Physiol. Endocrinol. Metab.,309:E852-E860 (2015).
    CrossRef
15. Rajeev Gandham, ME Sumathi, CD Dayanand, SR Sheela, P Kiranmayee. Apelin and its receptor: An Overview. Journal of Clinical and Diagnostic Research.,13(6):BE01-BE06 (2019).
    CrossRef
16. Kidoya H, Takakura N. Biology of the apelin-APJ axis in vascular formation. Biochem.,152(2):125-131 (2012).
    CrossRef
17. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. ,28:2023-2029 (2007).
    CrossRef
18. Leeper NJ, Tedesco MM, Kojima Y, Schultz GM, Kundu RK, Ashley EA, Tsao PS, Dalman RL, Quertermous T. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. J. Physiol. Heart. Circ. Physiol.,296:H1329-H1335 (2009).
    CrossRef
19. Inuzuka H, Nishizawa H, Inagaki A, Suzuki M, Ota S, Miyamura H, Miyazaki J, Sekiya T, Kurahashi H, Udagawa Y. Decreased expression of apelin in placentas from severe preeclampsia patients. Pregnancy.,32(4):410-421 (2013).
    CrossRef
20. MarzenaLaskowska, KatarzynaLaskowska, MahfozTerbosh, janOleszczuk. A comparison of maternal serum levels of endothelial nitric oxide Synthase, asymmetric dimethylarginine, and homocysteine in normal and preeclamptic pregnancies. Sci. Monit.,19:430-437 (2013).
    CrossRef
21. Gielen S, Sandri M, Erbs S, Adams V: Exercise-induced modulation of endothelial nitric oxide production. Pharm.Biotechnol.,12(9):1375-1384 (2011).
    CrossRef
22. George B. Stefano, Richard M. Kream: Reciprocal regulation of cellular nitric formation by nitric oxide synthase and nitrite reductase. Sci.Monit.,17(10):RA221-226 (2011).
    CrossRef
23. Myatt L, Brockman DE, Eis AL, Pollock JS. Immunohistochemical localization of nitric oxide synthase in the human placenta. ,14:487-495 (1993).
    CrossRef
24. Conrad KP, Vill M, McGuire PG, Dail WG, Davis AK. Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi. FASEB J., 7:1269-1276 (1993).
    CrossRef
25. Buttery LD, McCarthy A. Springall DR, Sullivan MH, Elder MG, Michel T, Polak JM. Endothelial nitric oxide Synthase in the human placenta: regional distribution and proposed regulatory role at the feto-maternal interface. ,15:257-265 (1994).
    CrossRef
26. Rutherford RA, McCarthy A, Sullivan MH, Elder MG, Polak JM, Wharton J. Nitric oxide synthase in human placenta and umbilical cord from normal, intrauterine growth-retarded and pre-eclamptic pregnancies. J.Pharmacol.,116(8):3099-3109 (1995).
    CrossRef
27. Conrad KP, Davis AK. Nitric oxide synthase activity in placentae from women with preeclampsia. ,16(8):691-699 (1995).
    CrossRef
28. Kulandavelu S, whiteley KJ, Qu D, Mu J, Bainbridge SA, Adamson SL. Endothelial nitric oxide synthase deficiency reduces uterine blood flow, spiral artery elongation and placental oxygenation in pregnant mice. ,60(1):231-238 (2012).
    CrossRef
29. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of ‘the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Gynecol., 122: 1122–1131 (2013).
30. Lissette C. Sanchez-Aranguren, Carlos E.prada, Carlos E.Riano-Medina and Marcos Lopez. Endothelial dysfunction and preeclampsia: role of oxidative stress. Physiol.,5:1-11 (2014).
    CrossRef
31. Dhananjaya BS, Venkatesh G, SendilKumadan D. Study of correlation between oxidative stress parameters and severity of preeclampsia. International Journal of Biological & Medical Research.,3(1): 1260-1262 (2012).
32. Adetunji O. Adeniji and Dolapo P. Oparinde. Comparison of lipid peroxidation and anti-oxidant activities in preeclmaptic and normal pregnancies in Nigerian population. Research Journal of Medical Sciences.,7(2): 40-43 (2013).
33. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: A new plasma marker of cardiopulmonary disease. Pept.,133(1-3):134-138 (2006).
    CrossRef
34. Kalea AZ, Batlle D. Apelin and ACE2 in cardiovascular disease. OpinInvestig Drugs.,11:273-282 (2010).
    CrossRef
35. Chengshu Wang, Xiaoli Liu, Desheng Kong, Xijing Qin, Yanqing Li, XuTeng, and Xianghua Huang. Apelin as a novel drug for treating preeclampsia. Expmental and Therapeutic Medicine., 14: 5917-5923 (2017).
36. Kim YJ, Park HS, Lee HY, Ha EH, Suh SH, Oh SK, Yoo HS. Reduced L-arginine level and decreased placental eNOS activity in preeclampsia. ,27(4-5):438-444 (2006).
    CrossRef
37. Zawiejska A, Wender-Ozegowska E, Iciek R, Brazert J. Concentrations of endothelial nitric oxide synthase, angiotensin-converting enzyme, vascular endothelial growth factor and placental growth factor in maternal blood and maternal metabolic status in pregnancy complicated by hypertensive disorders. Hum.Hypertens.,28(11):670-676 (2014).
    CrossRef
38. Motta-Mejia C, Kandzija N, Zhang W, Mhlomi V, Cerdeira AS, Burdujan A, Tannetta D, Dragovic R, Sargent IL, Redman CW, Kishore U, Vatish M. Placental Vesicles Carry Active Endothelial Nitric Oxide Synthase and Their Activity is Reduced in Preeclampsia. ,70(2):372-381 (2017).
    CrossRef
39. Choi JW, Im MW, Pai SH. Nitric oxide production increases during normal pregnancy and decreases in preeclampsia. Clin. Lab. Sci.,32(3): 257-263 (2002).
40. Nadkarni J, bahl J, Parekh P. Perinatal outcome in pregnancy associated hypertension. Pediatr.,38:174-178 (2001).
41. Odegard RA, Vatten LJ, Nilsen ST.Salvesen KA, AustgulenR.Preeclampsia and fetal growth. Gynecol.,96:950-965 (2000).
    CrossRef